ReN001

Type: Product
Name: ReN001
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Neil Woodford increases bet on stem cell therapies

Fund manager takes stake in ReNeuron up to 19.94pc Veteran fund manager Neil Woodford has put more money behind stem cell therapies by increasing his stake in ReNeuron His fund, Woodfod Investment Management, has bought 26,200,000 more shares in the Aim-listed ... [Published Telegraph - Oct 14 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

BIG PICTURE: ReNeuron at pivotal point in its history

Things are slotting nicely into place for ReNeuron ( LON:RENE ), the developer of novel stem cell therapies targeting areas of unmet or poorly met medical need. Earlier this week the company announced the appointment of Olav Hellebø, a highly experienced ... [Published Proactiveinvestors United Kingdom RSS feed - Sep 10 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

ReNeuron says dosing of patients in two clinical trials has started

ReNeuron ( LON:RENE ) said the first patients have been dosed in both of the ReN001 and ReN009 trials flagged in its June results statement. The ReN001 cell therapy candidate for stroke disability is undergoing a Phase II trial while the ReN009 cell ... [Published Proactiveinvestors United Kingdom website - Sep 02 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

ReNeuron upbeat after "transformational" year

Stem cell specialist ReNeuron ( LON:RENE )says it's upbeat after what it called a 'transformational' year, as it posted results for the year to end March. A share placing in July raised £25.3mln bolstering the balance sheet and will fund key second ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2014]
First reported May 16 2014 - Updated May 16 2014 - 1 reports

This week: Shoe Zone sizing up IPO, Flowtech powering towards AIM, Conroy Gold reaffirming strong portfolio

BLUR trading update,CGNR wide mineralised zones,Flowtech Fluidpower intention to float on AIM,Marimedia intention to float on AIM,PEG AGM Statement,RENE new data,RXB first day of dealings on AIM,Shoe Zone intention to float on AIM,XLM preliminary results,C21 ... [Published Proactiveinvestors United Kingdom RSS feed - May 16 2014]

Quotes

"The Phase IIPhase II clinical trial with ReN001 is on course to have generated six month follow-up data by the end of 2015. We also remain on course to announce results from the Phase I study with ReN009 in the first half of 2015" the company will tell shareholders at Tuesday's annual general meeting
"We remain on track to move into our world-class cell manufacturing facility in South Wales in the early part of next year, which we believe will become a major element of ReNeuron 's overall value proposition. "
...Rex Bionics " marketed products: REX Rehab and REX Personal, can be used by people with complete spinal cord injury, but also by a much broader potential customer base, including people with multiple sclerosis and muscular dystrophy. "
"We are delighted to have received these concurrent clinical trial approvals for our stroke and critical limb ischaemia programmes.  It is especially pleasing to have been given approval to use our second-generation CTXcryo cells in both of these new clinical trials. The fact that this new product variant is being deployed clinically much earlier than we had planned is illustrative of ReNeuron's ability, in collaboration with its various partners, to successfully innovate and sustain its commercial and competitive edge."

More Content

All (7) | News (6) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Neil Woodford increases bet on stem cell therapies [Published Telegraph - Oct 14 2014]
BIG PICTURE: ReNeuron at pivotal point in its h... [Published Proactiveinvestors United Kingdom RSS feed - Sep 10 2014]
ReNeuron says dosing of patients in two clinica... [Published Proactiveinvestors United Kingdom website - Sep 02 2014]
ReNeuron upbeat after "transformational" year [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2014]
This week: Shoe Zone sizing up IPO, Flowtech po... [Published Proactiveinvestors United Kingdom RSS feed - May 16 2014]
UK Clinical Trial Approvals [Published TrustNet - Mar 27 2014]
Support for Early Access to Medicines Scheme [Published TrustNet - Mar 14 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ReNeuron says dosing of patients in two clinica... [Published Proactiveinvestors United Kingdom website - Sep 02 2014]
ReNeuron ( LON:RENE ) said the first patients have been dosed in both of the ReN001 and ReN009 trials flagged in its June results statement. The ReN001 cell therapy candidate for stroke disability is undergoing a Phase II trial while the ReN009 cell ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.